{"id":1729,"date":"2022-04-15T13:52:18","date_gmt":"2022-04-15T13:52:18","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1729"},"modified":"2026-02-23T00:52:36","modified_gmt":"2026-02-23T00:52:36","slug":"contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/","title":{"rendered":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell)"},"content":{"rendered":"

Inherited mutations in PALB2<\/em> are the most common cause of familial breast cancer after BRCA1<\/em> and BRCA2 <\/em>but it is possible that current clinical genetic testing might be missing some cancer-causing mutations. <\/em>\u00a0For BRCA1 and BRCA2 many of the cancer-causing mutations involve changes in large sections of these genes (called large genomic rearrangements or LGRs) which need special tests to accuracy detect them. For PALB2, it is currently not known how common these LGRs are and therefore these special tests are not routinely performed. \u00a0We conducted the largest study to date of PALB2 LGRs in over 10,000 subjects and show that over 10% of mutation in PALB2 are LGRS and are likely not identified in routine testing. Our work provides strong support for PALB2<\/em> LGRs tests to be made standard of care in clinical genetic testing.\u00a0 (https:\/\/jmg.bmj.com\/content\/early\/2022\/04\/07\/jmedgenet-2021-108399<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"

Inherited mutations in PALB2 are the most common cause of familial breast cancer after BRCA1 and BRCA2 but it is possible that current clinical genetic testing might be missing some cancer-causing mutations. \u00a0For BRCA1 and BRCA2 many of the cancer-causing mutations involve changes in large sections of these genes (called large genomic rearrangements or LGRs) […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1729","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nContribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Inherited mutations in PALB2 are the most common cause of familial breast cancer after BRCA1 and BRCA2 but it is possible that current clinical genetic testing might be missing some cancer-causing mutations. \u00a0For BRCA1 and BRCA2 many of the cancer-causing mutations involve changes in large sections of these genes (called large genomic rearrangements or LGRs) [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-15T13:52:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T00:52:36+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell)\",\"datePublished\":\"2022-04-15T13:52:18+00:00\",\"dateModified\":\"2026-02-23T00:52:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/\"},\"wordCount\":162,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/\",\"name\":\"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2022-04-15T13:52:18+00:00\",\"dateModified\":\"2026-02-23T00:52:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/04\\\/15\\\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/","og_locale":"en_US","og_type":"article","og_title":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog","og_description":"Inherited mutations in PALB2 are the most common cause of familial breast cancer after BRCA1 and BRCA2 but it is possible that current clinical genetic testing might be missing some cancer-causing mutations. \u00a0For BRCA1 and BRCA2 many of the cancer-causing mutations involve changes in large sections of these genes (called large genomic rearrangements or LGRs) [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/","og_site_name":"JMG Contact blog","article_published_time":"2022-04-15T13:52:18+00:00","article_modified_time":"2026-02-23T00:52:36+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell)","datePublished":"2022-04-15T13:52:18+00:00","dateModified":"2026-02-23T00:52:36+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/"},"wordCount":162,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/","url":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/","name":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2022-04-15T13:52:18+00:00","dateModified":"2026-02-23T00:52:36+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/04\/15\/contribution-of-large-genomic-rearrangements-in-palb2-to-familial-breast-cancer-implications-for-genetic-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing (Contributed by Professor Ian Campbell)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1729"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1729\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}